Enterome, Dana-Farber partner on microbiome-derived mimics of tumor antigens

Enterome and Dana-Farber Cancer Institute partnered to validate the use of microbiome-derived antigens for cancer immunotherapies, expanding on the company's own discovery of onco-mimics, or bacterial antigens that mimic tumor antigens.

Enterome Bioscience S.A. (Paris, France) is using its onco-mimic discovery platform to search for antigens in the gut microbiome that share molecular similarity with known tumor antigens and neoantigens. The deal is the latest sign that companies looking to develop microbiome-based immunotherapies are turning to academic deals to uncover the targets and get a better handle on the biology (see “Checking Out the Microbiome”)...